July 29, 2020 -- InvestorsHub NewsWire -- via NextBigTicker --

PAO Group, Inc. (USOTC: PAOG) has had consistently high trading volume after announcing a management takeover and two pending acquisitions.  The PPS climbed rapidly from $0.0003 all the way to a new 52-Week High of $0.0059 and has since been consolidating well above both the 50 Day and 200 Day Moving Averages at a PPS between $0.0026 and $0.0035. 

Short sellers are actively covering.  PAOG is listed as one of the most shorted stocks on the OTC Short Report (https://www.otcshortreport.com/company/PAOG) based on data from FINRA’s Short Volume Report.  With the big recent volume taking the PPS to $0.0059 all above all above $0.0025, shorts are likely happy to be covering anywhere under $0.003.  The $0.003 PPS is likely a short squeeze trigger and solid trading volume above $0.003 is likely to see short converging contribution to PPS gains.

$14 Billion Cannabis Biopharmaceutical News

PAOG has its second acquisition for the week scheduled to close tomorrow, July 28.  This is the big one.  The company is acquiring a patented cannabis extraction operation from Kali-Extracts (KALY).  The operation comes with a drug called RespRx under development.  RespRx is a treatment for Chronic Obstructive Pulmonary Disease (COPD).  Across the eight major economic markets of the US, France, Germany, Italy, Spain, the UK, Japan, and Australia, the COPD treatment market is anticipated to rise from $9.9 billion in 2015 to around $14.1 billion by 2025.

The $14 Billion news has the potential to triger the PAOG PPS climb over a $0.01 PPS from its current $0.002 to $0.003 PPS range and go as high as $0.10. 

The patented cannabis extraction process acquisition might also be harboring a secret weapon against COVID-19.

In January, KALY announced the potential treatment of COVID-19 symptoms:

“Kali-Extracts, Inc. today highlighted that its RespRx CBD formulation could offer treatment for coronavirus symptoms.  KALY's CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.  The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's U.S. Patented Cannabis Extraction Process. In conjunction with the research already conducted and the next phase of research now moving forward, KALY has filed a new patent application specifically on its CPD formulation for symptoms associated with COPD and other similar respiratory conditionsKALY has also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.”

Multiple articles have recently been published from highly reputable sources on the potential for cannabis to treat COVID-19 symptoms. Here are just a few:

Forbes - Cannabis May Reduce Deadly COVID-19 Lung Inflammation: Researchers Explain Why

Forbes - Researchers Are Looking At Cannabis As A Potential Way To Prevent COVID-19

CBS - Researchers study cannabis as a treatment for COVID-19

The PAOG PPS was over $0.01 in January of 2019 and little is standing in the way of the PPS rapidly returning to the $0.01 level.


NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.


Other companies on the OTC Short Report most shorted list include: BBRW, BYOC and PVDG.

SOURCE: NextBigTicker